ranolazine ER / Generic mfg. - LARVOL DELTA

Quinidine-Induced Microvolt Electrocardiographic Alternans. (PubMed, Annu Int Conf IEEE Eng Med Biol Soc) - "The study population belongs to the "ECG Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects" database. Furthermore, ECGA magnitude seemed to reveal transient changes better than amplitude, resulting in more post-dose time points, especially in the range 3.5-7 hours after quinidine administration, at which ECGA was statistically different than at the pre-dose time point. Thus, ECGA appears to disclose the higher risk of arrhythmia associated with quinidine.Clinical Relevance- The present study provides a contribution to guide therapy involving quinidine through the analysis of its proarrhythmic risk by electrocardiographic alternans."

Journal • Cardiovascular

The Seattle Angina Questionnaire and Quality of Life in Chronic Coronary Syndrome: Opportunities for Implementation in Bulgarian Clinical Practice-A Narrative Review. (PubMed, Medicina (Kaunas)) - "Mechanism-tailored therapy maps to endotypes (e.g., VSA → CCB ± nitrates; MVA → beta-blocker/ACEi/statin ± ranolazine; obstructive CADGDMT ± PCI/CABG)... A clinically structured framework clarifies how the SAQ adds value beyond description-by informing triage, treatment selection, and follow-up across CCS phenotypes. This approach provides educational guidance and a practical blueprint for pilot implementation in Bulgaria."

HEOR • Journal • Review • Cardiovascular

Bioequivalence and Safety Study of Ranolazine Extended-Release Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: A Randomized, Open-Label, Single-Dose, Cross-Over, Comparative Pharmacokinetic Study. (PubMed, Clin Ther) - P1 | "The test formulation, ranolazine extended-release tablets, demonstrated a similar safety profile to the reference formulation, Ranexa, and was shown to be bioequivalent in healthy Chinese subjects in both fasting and fed conditions."

Journal • PK/PD data

The real-world safety profile of ranolazine: pharmacovigilance analysis of the FAERS database. (PubMed, Front Pharmacol) - "The results present vital safety information for physicians prescribing ranolazine. Notably, this study only identifies safety signals and does not establish causal relationships between ranolazine and the observed adverse events."

Adverse events • Journal • Real-world evidence • Atrial Fibrillation • Cardiovascular • CNS Disorders • Constipation • Coronary Artery Disease • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hypertension • Hypotension • Movement Disorders • Myocardial Infarction • Otorhinolaryngology • Pain • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Xerostomia

A QSPR study of coronary artery disease drugs using eccentricity-based indices. (PubMed, Sci Rep) - "This study advances QSPR modeling by using eccentricity-based graphical invariants, specifically designed to enhance the predictive accuracy for physicochemical properties of drugs used to treat coronary artery disease, including atorvastatin, simvastatin, rosuvastatin, aspirin, clopidogrel, metoprolol, atenolol, enalapril, lisinopril, amlodipine, diltiazem, nitroglycerin, isosorbide dinitrate, ranolazine, gemfibrozil, and fenofibrate. The experimental values were compared with forecasted data, revealing a strong correlation between them. This demonstrates the reliability of our regression models in assessing these vital physicochemical parameters."

Journal • Cardiovascular • Coronary Artery Disease

Development trend analysis of ranolazine, based on bibliometrics. (PubMed, Medicine (Baltimore)) - "Currently, the research focus in this field primarily centers on 3 key aspects: the anti-angina effect, the electrophysiological characteristics and anti-arrhythmic effect and other effects of ranolazine. The future research direction in this field is likely to focus on the neuroprotective effect of ranolazine, its antitumor metastasis effect and its effect on atrial fibrillation and diabetes patients on the basis of maintaining the current research focus."

Journal • Atrial Fibrillation • Cardiovascular • Diabetes • Metabolic Disorders • Oncology

Cost-Effectiveness Model of Ranolazine for Treating Chronic Stable Angina Patients From Kingdom of Saudi Arabia Perspective (ISPOR-EU 2025) - "This insight, along with the importance of stratifying outcomes by angina severity and including revascularization impacts, guided the development of a 1-year decision tree model which compared ranolazine+sublingual nitro-glycerine (SNG) against placebo+SNG and trimetazidine+SNG. Trimetazidine was selected as the comparator due to its lower cost, high prevalence (approximately 95%) in Saudi Arabian second-line treatments, and superior safety profile compared to Ivabradine... Ranolazine is a cost-effective treatment compared to placebo and trimetazidine from KSA payor perspective. These findings are vital for optimizing healthcare resource allocation and ensuring patient access amidst rising costs."

Clinical • Cost effectiveness • HEOR • Cardiovascular

Trends in Out-of-Pocket Spending for Drugs Under Medicare Part D in Coronary Artery Disease and the Impact of the Inflation Reduction Act (AHA 2025) - "C1 included ticagrelor, isosorbide mononitrate, and atorvastatin; C2 is C1 + ezetimibe; C3 is C2 +bempedoic acid; C4 is C2 + evolocumab; and C5 is C3 + icosapent ethyl and ranolazine. From 2020–2024, modest cost reductions were observed ( C5: $5,632 to $4,400). After the IRA cap in 2025, costs approached or reached $2,000 for all regimens. However, C1 and C2, previously low-cost, paradoxically saw significant OOP increases (C1: +$795, p = 0.0068; C2: +$878, p = 0.009), while C5 experienced a significant reduction (–$2,366, p = 0.005)."

Medicare • Reimbursement • US reimbursement • Cardiovascular • Coronary Artery Disease

THE SILENT THREAT: PRINZMETAL ANGINA PRESENTING AS POLYMORPHIC VENTRICULAR TACHYCARDIA (CHEST 2025) - "Suspecting ranolazine-induced QT prolongation in setting of bradycardia as the PMVT trigger, this home medication was discontinued, and a permanent pacemaker (PPM) was implanted help prevent further PMVT episodes... Prinzmetal angina remains an elusive diagnosis due to its intermittent presentation. Clinicians should maintain a high index of suspicion in patients with recurrent unexplained arrhythmias, as timely recognition and appropriate management can be life-saving."

Cardiovascular • Coronary Artery Disease • Ventricular Tachycardia

Spinal Cord Stimulation in the Management of Refractory Microvascular Angina (ASA 2025) - "A 40-year-old woman with refractory angina due to coronary microvascular dysfunction failed extensive anti-anginal therapy, including beta-blockers, calcium channel blockers, nitrates, and ranolazine...Five days later, she underwent permanent generator implantation. At three-month follow-up, symptom relief and functional improvement were sustained, confirming durable benefit from spinal cord stimulation."

Cardiovascular

Ranolazine neuroprotection against middle cerebral artery occlusion/reperfusion ischemic injury via modulation of brain-derived neurotrophic factor and brain mitochondrial tu translation elongation factor (TUFM). (PubMed, Metab Brain Dis) - "Moreover, ranolazine suppressed apoptosis by reducing the levels of apoptotic mediators such as cytochrome c, caspase-9, and caspase-3, and flow cytometry analysis revealed a significant decline in neuronal apoptosis, which further underscores its neuroprotective efficacy. Therefore, the novelty of this research lies in demonstrating that ranolazine exerts neuroprotective effects against ischemic brain injury by simultaneously modulating apoptotic pathways, restoring vital neurological factors (BDNF, TUFM, NRF-1, PGC-1α), improving mitochondrial function, reducing oxidative stress, and attenuating neuroinflammation, offering a novel multi-targeted therapeutic approach, meriting further clinical studies."

Journal • Cardiovascular • CNS Disorders • Inflammation • Ischemic stroke • Reperfusion Injury • Vascular Neurology • BDNF • CASP3 • CASP9 • CAT • FAP • GFAP • HIF1A • IL10 • IL6 • NRF1 • TNFA

Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug. (PubMed, Eur Heart J Cardiovasc Pharmacother) - "Our study, performed in a subset of the Italian CCS population, showed that Ran therapy was safe and associated with a long-term reduced AF incidence."

Journal • Real-world evidence • Atrial Fibrillation • Cardiovascular • Ventricular Tachycardia

Contemporary Antianginal Therapy. (PubMed, Am J Cardiovasc Drugs) - "Beta-blockers and calcium channel blockers remain the foundation of symptom management, while nitrates, ranolazine, ivabradine, and trimetazidine may be considered for refractory symptoms. Emerging interventional strategies and stem cell-based interventions show promise for patients with refractory angina who lack further revascularization options. The limited progress in novel pharmacologic development reinforces the need for ongoing research to refine therapeutic strategies for CMD and expand treatment options for patients with treatment-resistant angina."

Journal • Review • Cardiovascular

Discovery of platelet glycoprotein VI receptor antagonists and their neuroprotective activity: an in silico, in vitro, and in vivo study. (PubMed, 3 Biotech) - "Future studies focusing on the adapalene and ranolazine molecular mechanisms, bleeding risk, dose titration, and long-term safety while managing thrombotic disorders have to be investigated. The online version contains supplementary material available at 10.1007/s13205-025-04530-z."

Journal • Preclinical • Cardiovascular • CNS Disorders • Hematological Disorders • Neuroblastoma • Oncology • Solid Tumor • Thrombosis • CASP3 • HIF1A • SYK

CRAVE: Feasibility Trial for a Right Ventricular Failure Platform Trial (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: University of Alberta | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Aug 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Unraveling the pharmacological and therapeutic potential of Ranolazine beyond antianginal drug use: a new insight. (PubMed, Exp Biol Med (Maywood)) - "Besides its antianginal effect, RAN has recently revealed additional pharmacological properties such as neuroprotective, hepatoprotective, renal protective, cardioprotective, and antidiabetic effects and other beneficial pharmacological activities. We choose to write this current review paper to address the many hidden pharmacological and therapeutic potentials of RAN beyond its antianginal activity."

Journal • Review • Cardiovascular • Oncology

Significant Stagnancy in the Search and Use of New Antiarrhythmic Agents With Some Recent Beams of Hope. (PubMed, Curr Vasc Pharmacol) - "In this review of new antiarrhythmic agents, the advantages of sodium-glucose co-transporter inhibitors, and also those of pirfenidone, ranolazine, sotatercept, mirabegron, nintedanib, and melatonin are discussed. Some of these agents have been approved for other indications and repurposed for use in managing arrhythmias. Finding novel antiarrhythmic therapeutic approaches may be challenging for further research."

Journal • Atrial Fibrillation • Cardiovascular • Fibrosis • Immunology • Pain • Ventricular Tachycardia

RANOLAZINE RESCUE MITOCHONDRIAL FUNCTION AND DYNAMICS IN ALS PATIENT IPSC LOWER MOTOR NEURONS (PACTALS 2025) - "Our findings suggest that increased mitochondrial fission is a common feature in the soma of ALS derived iPSC-LMNs, and that Ranolozine can rescue mitochondrial dynamics. Further assessments of genomic and proteomic profiles will elucidate the mechanisms of action to improve ALS readouts."

Clinical • Amyotrophic Lateral Sclerosis • TARDBP

Ranolazine-Induced Type 1 Brugada Pattern. (PubMed, JACC Case Rep) - "Evidence of the safety of ranolazine in patients with BrS is lacking. A possible connection between ranolazine assumption and the unmasking of a type 1 Brugada pattern may question its use in these patients."

Journal • Atrial Fibrillation • Cardiovascular • Genetic Disorders • Myocardial Infarction

Optimising chronic coronary syndromes management: insights from bench to bedside (ESC-WCC 2025) - "The 2024 ESC Guidelines have differentiated between trimetazidine and ranolazine, classifying ranolazine as a Class IIa recommendation, alongside long-acting nitrates, while downgrading trimetazidine to Class IIb. This promotional Satellite Symposium has been organised and funded by Menarini Group. It is intended for healthcare professionals only."

Cardiovascular • Coronary Artery Disease

Long-term efficacy of endotype-based drug therapy on quality of life and symptom management in coronary vasomotion disorders (ESC-WCC 2025) - "Targeted endotype-based drug therapy can contribute decisively to a long-term improvement of symptoms and quality of life, especially in ANOCA patients with isolated coronary spasm or microvascular vasodilation disorder."

Clinical • HEOR • Cardiovascular • Coronary Artery Disease

Finerenone in the treatment of cardiac failure in patients with hypertrophic cardiomyopathy (ESC-WCC 2025) - "Basic therapy – beta-blockers (100%), SGLT2 inhibitors (47%), ARBs (89.5%), ranolazine (26.3%). Addition of finerenone therapy contributed to the reduction of heart failure symptoms (shortness of breath, increased tolerance to physical exertion). There was a decrease in the frequency of complaints of palpitations from 50% to 12.5% (p=0.03), shortness of breath from 87.5% to 56.25% (p=0.06) and weakness from 62.5% to 25% (p=0.03). In each of the examined patients with HCM, a decrease in NT-pro-BNP levels was noted from 38% to 182%, on average 79.9%."

Clinical • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hypertrophic Cardiomyopathy

Targeted medical treatment based on specific endotype defined by intracoronary physiology testing leads to rapid improvement of quality of life in symptomatic patients with INOCA (ESC-WCC 2025) - "Comparing medical treatment before and after invasive physiology testing - in patients with MVA significant increase in prescription of calcium channel blockers (CCB) (26.3% vs 94.7%, p<0.001), antianginal treatment like ranolazine or trimetazidine (15.8% vs 94.7%, p<0.001) and beta-blockers (BB) (42.1% vs 73.7%, p=0.05) was observed. Conclusion. The intracoronary physiology testing is safe, and provides precise diagnosis in patients whose symptoms were previously attributed to non-cardiac causes, allowing to start early treatment suitable for exact INOCA endotype, which leads to a rapid improvement in patients quality of life."

Clinical • HEOR • Cardiovascular

Ranolazine ameliorates palmitic acid-induced insulin resistance in HL-1 cardiomyocytes by Ca2+/ CaMKII modulation: an in vitro investigation and population-based cohort study (ESC-WCC 2025) - "In the population-based cohort study, our results indicated that ranolazine use was associated with a reduced risk of hyperglycemia after accounting for all measured confounders. Conclusions These findings suggest that RAN modulates key molecular pathways involved in diabetic cardiomyopathy."

Preclinical • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • CD36 • SCARB1 • SLC2A4

Investigating the effect of Ranolazine drug on the pathophysiology of asthma in a rat model. (PubMed, BMC Res Notes) - "Ranolazine treatment showed minimal impact on serum IgE levels in asthmatic rats, with a slight reduction that was statistically insignificant. However, Ranolazine treatment resulted in a significant decrease in perivascular and peribronchial inflammation levels compared to the asthmatic group, suggesting a potential therapeutic effect on lung histology changes associated with asthma pathophysiology."

Journal • Preclinical • Asthma • Cardiovascular • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases